Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 30, 2020
Samsung Biologics announced John Rim as its President and CEO.
read more
Samsung Biologics has announced an all-cash public tender offer to acquire PolyPeptide Group AG, valuing the peptide-focused contract development and manufacturing organization at approximately CHF 1.46 billion.
read more
Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year's BioProcess International Conference and ...
read more
Samsung Biologics, a contract development and manufacturing organization (CMDO), celebrated the one-year mark of Live Virtual Tour (LVT), a platform to provide remote site inspections for clients and regulatory agencies. The tool was developed and ...
read more
Samsung BioLogics has successfully performed N-1 (3,000L) perfusion with Alternating Tangential Flow device to supply the 15,000L commercial production process in the Plant 3 facility at its manufacturing site in Songdo, S. Korea.
read more
Monday, February 24, 2020
Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.
read more
Samsung Biologics announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.
read more
Tuesday, November 28, 2023
Samsung Biologics, a prominent global contract development and manufacturing organization (CDMO), hosted its inaugural Suppliers ESG Day at its Songdo headquarters and online, marking a significant step toward sharing environmental, social, and ...
read more
Monday, December 14, 2020
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
read more
Thursday, October 23, 2025
Samsung Biologics announced a shareholder-approved split of its business divisions, positioning itself as a pure-play contract development and manufacturing organization (CDMO). The move, passed with 99.9% approval at an extraordinary shareholders’ ...
read more
Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline.
read more
Samsung Biologics and TG Therapeutics have announced an expansion of a large-scale contract manufacturing deal for the supply of TG Therapeutics' ublituximab, an investigational anti-CD20 monoclonal antibody.
read more
Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins. Under the ...
read more
Monday, February 11, 2019
Samsung Bioepis announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.
read more
Thursday, December 03, 2020
Samsung Bioepis and Biogen announced the FDA has accepted for review the BLA for SB11, a proposed biosimilar referencing Lucentis.
read more